Files in this item
Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes : a systematic qualitative review
Item metadata
dc.contributor.author | Menown, Sara J. | |
dc.contributor.author | Tello, Javier A. | |
dc.date.accessioned | 2021-09-23T16:30:05Z | |
dc.date.available | 2021-09-23T16:30:05Z | |
dc.date.issued | 2021-10-01 | |
dc.identifier | 275856037 | |
dc.identifier | 5c1e58db-5639-4340-8522-dfebbaf55732 | |
dc.identifier | 85114792309 | |
dc.identifier | 000695147600001 | |
dc.identifier.citation | Menown , S J & Tello , J A 2021 , ' Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes : a systematic qualitative review ' , Advances in Therapy , vol. 38 , no. 10 , pp. 5025–5045 . https://doi.org/10.1007/s12325-021-01900-w | en |
dc.identifier.issn | 1865-8652 | |
dc.identifier.other | RIS: urn:3DB76C0790947CE65EF1160BECD4D5F7 | |
dc.identifier.other | RIS: Menown2021 | |
dc.identifier.uri | https://hdl.handle.net/10023/24016 | |
dc.description.abstract | Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs. | |
dc.format.extent | 21 | |
dc.format.extent | 1012606 | |
dc.language.iso | eng | |
dc.relation.ispartof | Advances in Therapy | en |
dc.subject | Menopause | en |
dc.subject | Vasomotor symptoms | en |
dc.subject | Hot flushes/flashes | en |
dc.subject | Neurokinin 3 receptor antagonist | en |
dc.subject | Fezolinetant | en |
dc.subject | Elinzanetant (NT-814) | en |
dc.subject | MLE4901 | en |
dc.subject | Serotonin Norepinephrine Reuptake Inhibitor | en |
dc.subject | Venlafaxine | en |
dc.subject | Desvenlafaxine | en |
dc.subject | RG Gynecology and obstetrics | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | MCC | en |
dc.subject.lcc | RG | en |
dc.subject.lcc | RM | en |
dc.title | Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes : a systematic qualitative review | en |
dc.type | Journal item | en |
dc.contributor.institution | University of St Andrews. Centre for Biophotonics | en |
dc.contributor.institution | University of St Andrews. Cellular Medicine Division | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.identifier.doi | 10.1007/s12325-021-01900-w | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.